title: Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS.
abstract: The delivery of nutrients to the gastrointestinal tract after food ingestion activates the secretion of several gut-derived mediators, including the incretin hormone glucagon-like peptide 1 (GLP-1). GLP-1 receptor agonists (GLP-1RA), such as exenatide and liraglutide, are currently employed successfully in the treatment of patients with type 2 diabetes mellitus. GLP-1RA improve glycaemic control and stimulate satiety, leading to reductions in food intake and body weight. Besides gastric distension and peripheral vagal nerve activation, GLP-1RA induce satiety by influencing brain regions involved in the regulation of feeding, and several routes of action have been proposed. This review summarises the evidence for a physiological role of GLP-1 in the central regulation of feeding behaviour and the different routes of action involved. Also, we provide an overview of presently available data on pharmacological stimulation of GLP-1 pathways leading to alterations in CNS activity, reductions in food intake and weight loss.
authors: Diabetes Centre, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands Department of Endocrinology and Metabolism, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
authors: L
authors: L
authors: van Bloemendaal
authors: J S
authors: JS
authors: Ten Kulve
authors: S E
authors: SE
authors: la Fleur
authors: R G
authors: RG
authors: Ijzerman
authors: M
authors: M
authors: Diamant
mesh_terms: D000818:Animals; D001066:Appetite / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects*; D002490:Central Nervous System / Q000187:drug effects* / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use*; D006801:Humans
chemical_list: D052216:Glucagon-Like Peptide 1
keywords: CNS; feeding behaviour; glucagon-like peptide 1; obesity; type 2 diabetes